TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07290062: A Phase 1, Multicenter, Open-label, Dose-Finding Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection of INS1202 in Patients With Amyotrophic Lateral Sclerosis

Sponsor: Insmed Gene Therapy LLC · Phase: PHASE1 · Area: RARE_ORPHAN · Target Enrollment: 23 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$420,240

Rescue Site Savings

+$280,160

Unlock Full NCT07290062 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07290062 Rescue Dossier →